Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6162802 | SANDOZ | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
Dec, 2017
(6 years ago) |
Lotrel is owned by Sandoz.
Lotrel contains Amlodipine Besylate; Benazepril Hydrochloride.
Lotrel has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lotrel are:
Lotrel was authorised for market use on 03 March, 1995.
Lotrel is available in capsule;oral dosage forms.
Lotrel can be used as method of treating hypertension.
The generics of Lotrel are possible to be released after 19 December, 2017.
Drugs and Companies using AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE ingredient
Market Authorisation Date: 03 March, 1995
Treatment: Method of treating hypertension
Dosage: CAPSULE;ORAL